Original Research

DOI: 10.4244/EIJ-D-26-00158

Prosthesis-patient mismatch with intra-annular self-expanding valves: an analysis of the PORTICO IDE trial

Gregory P. Fontana1, MD; Ron Waksman2, MD; Arash Salemi3, MD; Marc Cohen3, MD; William Abernethy4, MD; James Hermiller5, MD; Craig Baker6, MD; Joseph Montarello7, MD; Neal Kleiman8, MD; Lars Sondergaard9,10, MD; Eric Gnall11, MD; Roberto Rodriguez11, MD; Hemal Gada12, MD; William Brinkman13, MD; Neil J. Weissman2,14, MD; Paul Mahoney15, MD; Raj Makkar16, MD

Abstract

Background: Aortic valve replacement in small aortic annuli is associated with an increased risk of impaired haemodynamics.

Aims: We sought to evaluate haemodynamic outcomes and prosthesis-patient mismatch (PPM) in aortic stenosis (AS) patients treated with Portico, Evolut, and SAPIEN 3 transcatheter aortic valves (TAVs) in small (diameter ≤23 mm) and large (diameter >23 mm) aortic annuli.

Methods: PORTICO IDE was a prospective, multicentre, international, premarket randomised controlled trial comparing Portico to Evolut and SAPIEN 3 TAVs. An independent core laboratory evaluated the mean transvalvular pressure gradient (MG) and the effective orifice area (EOA), and PPM was calculated based on the core lab results.

Results: A total of 675 patients with severe AS at high or extreme surgical risk were included (Portico: 362 patients; Evolut: 109; SAPIEN 3: 204). At 30 days, the EOA and rates of severe PPM in small aortic annuli were similar between Portico and Evolut (EOA 1.65 cm2 vs 1.78 cm2; p=0.09; PPM 3.3% vs 3.0%; p=1.0) with a higher MG (8.5 mmHg vs 6.9 mmHg; p=0.034) for Portico. No significant differences were observed between Portico and Evolut for large aortic annuli (MG 8.3 mmHg vs 7.4 mmHg; p=0.069; EOA 1.93 cm2 vs 2.02 cm2; p=0.18; PPM 5.4% vs 3.2%; p=0.83). Portico was superior to SAPIEN 3 in both small (MG 8.5 mmHg vs 13.7 mmHg; p<0.0001; EOA 1.65 cm2 vs 1.40 cm2; p<0.0001; PPM 3.3% vs 26.3%; p<0.0001) and large annuli (MG 8.3 mmHg vs 10.9 mmHg; p<0.0001; EOA 1.93 cm2 vs 1.67 cm2; p<0.0001; PPM 5.4% vs 10.9%; p=0.0014). At 5 years, the rate of structural valve deterioration in patients with small aortic annuli was significantly lower in patients treated with Portico (2.2%) versus SAPIEN 3 (13.9%; p=0.03).

Conclusions: Haemodynamic performance was similar for the intra-annular Portico and supra-annular Evolut. Portico haemodynamics outperformed the balloon-expandable SAPIEN 3 for PPM and mean gradient in both small and large aortic annuli.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 22 Number 13
Jul 6, 2026
Volume 22 Number 13
View full issue


Key metrics

Suggested by Cory

Original Research

10.4244/EIJ-D-24-00966 Jul 7, 2025
Intra- versus supra-annular self-expanding transcatheter heart valves in small aortic annuli
Yamamoto M et al

Original Research

10.4244/EIJ-D-25-00937 Feb 2, 2026
Intra-annular self-expanding or balloon-expandable TAVI in small annuli: the NAVULTRA registry
Cannata S et al

Clinical research

10.4244/EIJ-D-23-00011 Jul 17, 2023
Transcatheter aortic valve implantation in patients with extra-small aortic annuli
Tirado-Conte G et al
free

10.4244/EIJV9SSA21 Sep 15, 2013
St. Jude Medical Portico™ transapical technology
Cheung A et al
free

Original Research

10.4244/EIJ-D-25-00682 Nov 14, 2025
Long-term outcomes and durability of balloon-expandable TAVI in small and large annuli
Yamamoto M et al
Trending articles
334.45

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
83.8

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
37.95

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.05

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
28.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
28.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.25

State-of-the-Art

10.4244/EIJ-D-24-00387 Jul 21, 2025
Advances in coronary imaging of atherosclerotic plaques
Garcia-Garcia H et al
free
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved